Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $51.42 Analyst target: $85.63 Upside: 66.53%
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
See the full interactive analysis & chart →Informational only — not investment advice.